

Research Article

Novel Compound Heterozygous *PRKN* Variants in a Han-Chinese Family with Early-Onset Parkinson's Disease

Kuan Fan ^{1,2}, Pengzhi Hu ^{1,3}, Chengyuan Song ⁴, Xiong Deng ¹, Jie Wen ¹,
Yiming Liu ⁴, and Hao Deng ^{1,5}

¹Center for Experimental Medicine, The Third Xiangya Hospital, Central South University, Changsha, China

²Department of Neurology, Guizhou Provincial People's Hospital, Guiyang, China

³Department of Radiology, The Third Xiangya Hospital, Central South University, Changsha, China

⁴Department of Neurology, The Qilu Hospital, Shandong University, Jinan, China

⁵Department of Neurology, The Third Xiangya Hospital, Central South University, Changsha, China

Correspondence should be addressed to Yiming Liu; liuym@sdu.edu.cn and Hao Deng; hdeng008@yahoo.com

Received 29 June 2019; Revised 26 September 2019; Accepted 23 October 2019; Published 23 December 2019

Academic Editor: Jan Aasly

Copyright © 2019 Kuan Fan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Genetic factors are thought to play an important role in the pathogenesis of Parkinson's disease (PD), particularly early-onset PD. The *PRKN* gene is the primary disease-causing gene for early-onset PD. The details of its functions remain unclear. This study identified novel compound heterozygous variants (p.T240K and p.L272R) of the *PRKN* gene in a Han-Chinese family with early-onset PD. This finding is helpful in the genetic diagnosis of PD and also the functional research of the *PRKN* gene.

1. Introduction

Parkinson's disease (PD) is the second most frequent neurodegenerative disease after Alzheimer's disease [1]. Parkinsonism, the core clinical feature of PD, is defined as slowly progressive bradykinesia combined with rest tremor or rigidity [2]. The etiology of PD remains enigmatic, while environmental and genetic factors are thought to be involved in [3]. Currently, 23 disease-causing loci and 19 genes have been identified for PD and recorded in the Online Mendelian Inheritance in Man (OMIM) [4]. Although PD mainly affects those over 50, early-onset PD (EOPD) patients, whose motor disorder symptoms appear before age 40, account for 3–5% of all PD patients worldwide [5]. EOPD's primary genetic type is autosomal recessive juvenile parkinsonism (AR-JP, OMIM 600116) caused by homozygous or compound heterozygous mutations in the parkin RBR E3 ubiquitin protein ligase gene (*PRKN*) [6]. It has parkinsonism symptoms, but may be a different disease entity from late-onset sporadic PD. This is suggested by more dystonia at onset, better levodopa responsiveness,

slower disease progression, sleep benefit, and lower frequencies of nonmotor symptoms and Lewy bodies [7–9].

This gene encodes the parkin protein which could ubiquitinate numerous mitochondrial outer membrane proteins resulting in autophagy of damaged mitochondria, and *PRKN* mutations caused mitochondrial quality control deficiencies and neuron death [10]. The parkin protein has been intensely studied due to its complex activation mechanisms and suppressive roles in various tumors [11, 12]. This study reports on new compound heterozygous variants in the *PRKN* gene in a family with EOPD (Figure 1). This finding expands the *PRKN*-associated PD genetic spectrum and may provide new insights into parkin protein structures and functions.

2. Materials and Methods

A Han-Chinese family with EOPD was recruited from China's Shandong Province (Figure 1(a)). The proband, her brother, and son were examined and diagnosed by two experienced neurologists. Two hundred unrelated healthy




FIGURE 1: (a) Pedigree of the family with EOPD. The arrow indicates the proband. (b) DNA sequencing of the c.719C > A variant in the *PRKN* gene. (c) DNA sequencing of the c.815T > G variant in the *PRKN* gene. (d) Conservation analysis of the parkin p.T240 amino acid residue. (e) Conservation analysis of the parkin p.L272 amino acid residue.

Han-Chinese older than 40 were enrolled as controls. This study was approved by the Institutional Review Board of the Third Xiangya Hospital of Central South University, Changsha, Hunan, China. After written informed consents were obtained, peripheral venous blood samples were taken from all participants. gDNA isolated from the proband (II: 2) was target captured by a PD-associated gene panel. Subsequently, paired-end sequencing using Illumina HiSeq X-ten platform (Illumina Inc., USA) was performed. All potential variants were filtered according to the Single Nucleotide Polymorphism database, the 1000 Genomes Project, and the Exome Aggregation Consortium database.

Coding indels, potential splice-site changes, and non-synonymous single-nucleotide variants in exons with minor allele frequency $<10^{-3}$ were considered as pathogenic candidates. Sanger sequencing verified candidate variants using an ABI3500 sequencer (Applied Biosystems Inc., USA) [13]. Sorting Intolerant from Tolerant (SIFT) and Combined Annotation Dependent Depletion (CADD) predicted the potential pathogenic effects of variants. The Basic Local Alignment Search Tool analyzed amino acid sequence conservations. The methods of targeted sequencing and Sanger sequencing are detailed in the Supplementary Materials.

TABLE 1: Reported variants in the 240th codon of the *PRKN* gene.

Nucleotide change	Amino acid change	Identifier	MAF (gnomAD)	SIFT		CADD score ^a	Reported patients ^b
				Score	Prediction		
c.719C > A	p.T240K	rs137853054	7.954×10^{-6}	0.01	Damaging	23.6	1
c.719C > T	p.T240M	rs137853054	3.465×10^{-4}	0.00	Damaging	23.8	13 [6, 14–20]
c.719C > G	p.T240R	—	—	0.00	Damaging	23.4	1 [21]
c.718A > G	p.T240A	—	—	1.00	Tolerated	14.97	2 [15]
c.718A > T	p.T240S	rs1194371893	7.954×10^{-6}	0.03	Damaging	21.8	—
c.720G > A	p.T240=	rs769882260	3.536×10^{-5}	—	—	5.479	—
c.720G > C	p.T240=	rs769882260	3.977×10^{-6}	—	—	4.599	—

MAF, minor allele frequency; gnomAD, Genome Aggregation Database; SIFT, Sorting Intolerant from Tolerant; CADD, Combined Annotation Dependent Depletion. ^aPHRED-scaled CADD score. ^bReported patients with *PRKN* variants in homozygous or compound heterozygous states.

TABLE 2: Reported variants in the 272nd codon of the *PRKN* gene.

Nucleotide change	Amino acid change	Identifier	MAF (gnomAD)	Hydropathy index	SIFT		CADD score ^a	Reported patients ^b
					Score	Prediction		
c.815T > G	p.L272R	—	—	-4.5	0.00	Damaging	29.2	1
c.814C > T	p.L272F	rs141366047	3.980×10^{-6}	2.8	0.00	Damaging	25.6	—
c.814C > G	p.L272V	rs141366047	1.194×10^{-5}	4.2	0.05	Damaging	24.4	—
c.814C > A	p.L272I	rs141366047	9.553×10^{-5}	4.5	0.01	Damaging	25.1	—
c.816C > T	p.L272 =	rs143902760	1.322×10^{-3}	3.8	—	—	9.553	—

MAF, minor allele frequency; gnomAD, Genome Aggregation Database; SIFT, Sorting Intolerant from Tolerant; CADD, Combined Annotation Dependent Depletion. ^aPHRED-scaled CADD score. ^bReported patients with *PRKN* variants in homozygous or compound heterozygous states.

3. Results

3.1. Clinical Features. The age at onset of the proband (II:2) was 32 years. The initial symptoms were slowness and rest tremor in her right arm, and tightness appeared one year later. These motor symptoms slowly progressed and spread to the right leg and contralateral limbs over a period of six years. Levodopa therapy significantly improved motor symptoms as of her first examination at age 35 years, but detailed evaluation was not performed. At her latest evaluation, at age 39 years, clinically established PD was diagnosed on the basis of prominent bradykinesia symptom and other PD-related symptoms, including rest tremor, rigidity, face masking, numbness, difficulty falling asleep, olfactory impairment, constipation, mild cognitive impairment, depression, and anxiety. Her MDS Unified Parkinson's Disease Rating Scale motor score was 9 (on)/14 (off), and Mini-Mental State Examination score was 22. Skull CT and MRI results, blood and urine copper levels, and ceruloplasmin were all normal. No movement disorders or other nervous system disorders were found in her son (III:1) or older brother (II:1).

3.2. Molecular Findings. After target capture sequencing and filtering, only the p.T240K (c.719C > A, rs137853054) and p.L272R (c.815T > G) variants of *PRKN* gene were considered as pathogenic candidates in the known monogenic PD-causing genes. Subsequent Sanger sequencing confirmed both in the proband (Figures 1(b) and 1(c)). The p.T240K variant was found in her son (III:1). The two variants were absent from her older brother (II:1) and from the 200 normal controls. The p.T240K variant has a very low recorded heterozygous state frequency in the Genome Aggregation Database (gnomAD,

7.954×10^{-6}). SIFT and CADD predicted the c.719C > A (p.T240K) variant as damaging (Table 1). The p.L272R variant has not been reported in the gnomAD and also has a damaging prediction in SIFT and CADD analysis (Table 2). Multi-sequence alignment shows that the leucine at position 272 is phylogenetically conserved from fruit flies to humans (Figure 1(e)). These data indicate that the compound heterozygous variants, p.T240K and p.L272R, are probably disease-causing for EOPD in this family.

4. Discussion

The parkin protein is a 465-amino acid E3 ubiquitin ligase of the RING-between-RING (RBR) family, which could catalyze the transfer of ubiquitin from the E2 conjugating enzyme to substrate proteins [10]. Numerous recent studies attempted to determine the relationship between the parkin protein structure and its functions through *in vitro* and animal experiments. The most direct and compelling evidence for protein structure change effects remains the mutations, particularly missense mutations detected in patients. Approximately 25% of all *PRKN* gene mutations have been found in the RING1 domain, which is considered to have a binding site for the E2 conjugating enzyme and be important to parkin activation due to its interactions with Ser65-phosphorylated ubiquitin and the Ubl domain (Figure 2) [10, 14, 15, 21–29]. The detailed molecular structure of parkin remains unclear, which results in several different activation and catalysis models [30].

In this study, clinically established EOPD and extensive nervous system impairment were suggested by the presence of three cardinal motor symptoms and multiple nonmotor symptoms in the proband. Two missense variants (p.T240K




FIGURE 2: (a) Domain structure and missense variants associated with autosomal recessive parkinsonism detected in the RING1 domain of parkin protein [10, 14, 15, 21, 23–28]. Two variants detected in this study are highlighted in bold. β -Strand and α -helix are in dark blue and pink, respectively. Zinc-binding cysteines are signed with orange dots. (b) Cartoon representation of the p.T240K and p.L272R variants in parkin protein by PyMOL. Parkin protein crystal structure (PDB code 5C1Z) was used as a template [29]. Variants are shown as red stick models, and Zn^{2+} are shown as spheres. pUb, Ser65-phosphorylated ubiquitin.

and p.L272R) with potential pathogenicity are located in the RING1 domain and had not been previously reported in PD patients. Although the sequence conservation of threonine at position 240 is lower than that of leucine at position 272 (Figures 1(d) and 1(e)), there have been at least 16 reported PD patients with *PRKN* p.T240M, p.T240R, or p.T240A variants in homozygous or compound heterozygous states (Table 1) [6, 14–21]. This amino acid is in the first Zn-binding loop of the RING1 domain which has been regarded as the E2 binding site of parkin [31]. The p.T240R mutation has been found to change the E2 binding interface and destroy the autoubiquitination activation of parkin protein and lead to EOPD [31, 32]. The first α -helix (260–273) of the RING1 domain was reported as the binding site for the Ubl domain, which adjoins the RING1 domain through hydrophobic interaction to block E2 access [10, 33]. Three other missense variants (p.L272I, p.L272V, and p.L272F) and one synonymous variant in the 272nd codon have been recorded. However, no pathogenic evidence has been

reported for these four variants, which may be due to low allele frequencies in generating populations and preservation of hydrophobicity (Table 2). The p.L272R, resulting in materially hydrophilic alternation, is more likely to disrupt protein folding and affect its function, especially in a compact protein stabilized by numerous hydrophobic interactions such as parkin (Table 2) [34, 35]. Investigating the structural changes resulting from the p.L272R variant may contribute to understanding parkin domain interactions and their potential function. More evidence including segregation information and functional research is needed to classify the two variants as pathogenic or likely pathogenic variants according to the American College of Medical Genetics and Genomics guidelines for variants interpretation [36].

In conclusion, the novel compound heterozygous variants of *PRKN* gene, p.T240K and p.L272R, were identified as the probable genetic cause for EOPD in a family with clinically established EOPD. These two missense variants

both lead to amino acid changes in the RING1 domain. This finding has potential value for functional research of the *PRKN* gene and genetic diagnosis of PD. Further studies are warranted to clarify their pathogenicity and may offer deeper understanding of the detailed functional effects.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Disclosure

Kuan Fan and Pengzhi Hu should be considered co-first authors.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This work was supported by the National Key Research and Development Program of China (2016YFC1306604), National Natural Science Foundation of China (81873686, 81670216, 81800219, and 30970990), Natural Science Foundation of Hunan Province (2019JJ50927, 2018JJ2660, and 2018JJ2556), Science and Technology Program of Hunan Province (2017SK50131), Scientific Research Project of Health and Family Planning Commission of Hunan Province (B20180760 and B20180729), Guizhou Provincial Science and Technology Foundation (20191196), and Hunan Provincial Innovation Foundation for Postgraduate (CX20190075), China.

Supplementary Materials

The detailed methods of targeted sequencing and Sanger sequencing used in this study are included. (*Supplementary Materials*)

References

- [1] D. Hirtz, D. J. Thurman, K. Gwinn-Hardy, M. Mohamed, A. R. Chaudhuri, and R. Zalutsky, "How common are the "common" neurologic disorders?," *Neurology*, vol. 68, no. 5, pp. 326–337, 2007.
- [2] R. B. Postuma, D. Berg, M. Stern et al., "MDS clinical diagnostic criteria for Parkinson's disease," *Movement Disorders*, vol. 30, no. 12, pp. 1591–1601, 2015.
- [3] L. V. Kalia and A. E. Lang, "Parkinson's disease," *The Lancet*, vol. 386, no. 9996, pp. 896–912, 2015.
- [4] H. Deng, P. Wang, and J. Jankovic, "The genetics of Parkinson disease," *Ageing Research Reviews*, vol. 42, pp. 72–85, 2018.
- [5] A. Schrag and J. M. Schott, "Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism," *The Lancet Neurology*, vol. 5, no. 4, pp. 355–363, 2006.
- [6] M. Periquet, M. Latouche, E. Lohmann et al., "Parkin mutations are frequent in patients with isolated early-onset parkinsonism," *Brain*, vol. 126, no. 6, pp. 1271–1278, 2003.
- [7] E. Lohmann, M. Periquet, V. Bonifati et al., "How much phenotypic variation can be attributed to parkin genotype?," *Annals of Neurology*, vol. 54, no. 2, pp. 176–185, 2003.
- [8] M. Pouloupoulos, O. A. Levy, and R. N. Alcalay, "The neuropathology of genetic Parkinson's disease," *Movement Disorders*, vol. 27, no. 7, pp. 831–842, 2012.
- [9] M. Kasten, C. Hartmann, J. Hampf et al., "Genotype-phenotype relations for the Parkinson's disease genes parkin, *PINK1*, *DJ1*: MDSGene systematic review," *Movement Disorders*, vol. 33, no. 5, pp. 730–741, 2018.
- [10] J. W. Harper, A. Ordureau, and J.-M. Heo, "Building and decoding ubiquitin chains for mitophagy," *Nature Reviews Molecular Cell Biology*, vol. 19, no. 2, pp. 93–108, 2018.
- [11] K. Wahabi, A. Perwez, and M. A. Rizvi, "Parkin in Parkinson's disease and cancer: a double-edged sword," *Molecular Neurobiology*, vol. 55, no. 8, pp. 6788–6800, 2018.
- [12] N. Panicker, V. L. Dawson, and T. M. Dawson, "Activation mechanisms of the E3 ubiquitin ligase parkin," *Biochemical Journal*, vol. 474, no. 18, pp. 3075–3086, 2017.
- [13] Q. Chen, L. Yuan, X. Deng et al., "A missense variant p.Ala117Ser in the transthyretin gene of a Han Chinese family with familial amyloid polyneuropathy," *Molecular Neurobiology*, vol. 55, no. 6, pp. 4911–4917, 2018.
- [14] F. Sironi, P. Primignani, M. Zini et al., "Parkin analysis in early onset Parkinson's disease," *Parkinsonism & Related Disorders*, vol. 14, no. 4, pp. 326–333, 2008.
- [15] B. R. Al-Mubarak, S. A. Bohlega, T. S. Alkhairallah et al., "Parkinson's disease in Saudi patients: a genetic study," *PLoS One*, vol. 10, no. 8, Article ID e0135950, 2015.
- [16] L. de Mena, L. Samaranch, E. Coto et al., "Mutational screening of PARKIN identified a 3' UTR variant (rs62637702) associated with Parkinson's disease," *Journal of Molecular Neuroscience*, vol. 50, no. 2, pp. 264–269, 2013.
- [17] R. H. Madegowda, A. Kishore, and A. Anand, "Mutational screening of the parkin gene among South Indians with early onset Parkinson's disease," *Journal of Neurology, Neurosurgery & Psychiatry*, vol. 76, no. 11, pp. 1588–1590, 2005.
- [18] M. Amboni, M. T. Pellecchia, A. Cozzolino et al., "Cerebellar and pyramidal dysfunctions, palpebral ptosis and weakness as presenting symptoms of PARK-2," *Movement Disorders*, vol. 24, no. 2, pp. 303–305, 2009.
- [19] S. T. Camargos, L. O. Dornas, P. Momeni et al., "Familial parkinsonism and early onset Parkinson's disease in a Brazilian movement disorders clinic: phenotypic characterization and frequency of *SNCA*, *PRKN*, *PINK1*, and *LRRK2* mutations," *Movement Disorders*, vol. 24, no. 5, pp. 662–666, 2009.
- [20] H. Deng, W.-D. Le, C. B. Hunter et al., "Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations," *Archives of Neurology*, vol. 63, no. 2, pp. 273–277, 2006.
- [21] N. Hattori, H. Matsumine, S. Asakawa et al., "Point mutations (Thr240Arg and Ala311Stop) in the Parkin gene," *Biochemical and Biophysical Research Communications*, vol. 249, no. 3, pp. 754–758, 1998.
- [22] S. Mitsuyama, M. Ohtsubo, S. Minoshima, and N. Shimizu, "The KM-parkin-DB: a sub-set MutationView database specialized for PARK2 (PARKIN) variants," *Human Mutation*, vol. 36, no. 8, pp. E2430–E2440, 2015.
- [23] J. M. Hertz, K. Ostergaard, I. Juncker et al., "Low frequency of parkin, tyrosine hydroxylase, and GTP cyclohydrolase I gene mutations in a Danish population of early-onset Parkinson's disease," *European Journal of Neurology*, vol. 13, no. 4, pp. 385–390, 2006.

- [24] J.-F. Guo, B. Xiao, B. Liao et al., "Mutation analysis of Parkin, *PINK1*, *DJ-1* and *ATP13A2* genes in Chinese patients with autosomal recessive early-onset Parkinsonism," *Movement Disorders*, vol. 23, no. 14, pp. 2074–2079, 2008.
- [25] K. S. Marder, M. X. Tang, H. Mejia-Santana et al., "Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study," *Archives of Neurology*, vol. 67, no. 6, pp. 731–738, 2010.
- [26] C. Scherfler, N. L. Khan, N. Pavese et al., "Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism," *Brain*, vol. 127, no. 6, pp. 1332–1342, 2004.
- [27] R.-M. Wu, R. Bounds, S. Lincoln et al., "Parkin mutations and early-onset parkinsonism in a Taiwanese cohort," *Archives of Neurology*, vol. 62, no. 1, pp. 82–87, 2005.
- [28] H. Chen, X. Huang, L. Yuan et al., "A homozygous parkin p.G284R mutation in a Chinese family with autosomal recessive juvenile parkinsonism," *Neuroscience Letters*, vol. 624, pp. 100–104, 2016.
- [29] A. Kumar, J. D. Aguirre, T. E. Condos et al., "Disruption of the autoinhibited state primes the E3 ligase parkin for activation and catalysis," *The EMBO Journal*, vol. 34, no. 20, pp. 2506–2521, 2015.
- [30] C. Arkinson and H. Walden, "Parkin function in Parkinson's disease," *Science*, vol. 360, no. 6386, pp. 267–268, 2018.
- [31] J.-F. Trempe, V. Sauvé, K. Grenier et al., "Structure of parkin reveals mechanisms for ubiquitin ligase activation," *Science*, vol. 340, no. 6139, pp. 1451–1455, 2013.
- [32] H. Shimura, N. Hattori, S.-I. Kubo et al., "Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase," *Nature Genetics*, vol. 25, no. 3, pp. 302–305, 2000.
- [33] E. Walinda, D. Morimoto, K. Sugase, and M. Shirakawa, "Dual function of phosphoubiquitin in E3 activation of parkin," *Journal of Biological Chemistry*, vol. 291, no. 32, pp. 16879–16891, 2016.
- [34] J. Kyte and R. F. Doolittle, "A simple method for displaying the hydropathic character of a protein," *Journal of Molecular Biology*, vol. 157, no. 1, pp. 105–132, 1982.
- [35] M. Seirafi, G. Kozlov, and K. Gehring, "Parkin structure and function," *FEBS Journal*, vol. 282, no. 11, pp. 2076–2088, 2015.
- [36] S. Richards, On behalf of the ACMG Laboratory Quality Assurance Committee, N. Aziz et al., "Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology," *Genetics in Medicine*, vol. 17, no. 5, pp. 405–424, 2015.



Hindawi

Submit your manuscripts at
www.hindawi.com

